NCT06469710Recruiting
A Trial to Evaluate the Effect of Applying Leukapheresis to Enrich CTCs in mPCa Patients
A Trial to Evaluate the Effect of Applying Leukapheresis to Enrich CTCs in Patients With Metastatic Prostate Cancer
Source: ClinicalTrials.gov · Last updated 11 Aug 2026
Brief summary (registry, in English)
The goal of this observational study is to compare the number of CTCs enriched by both sampling methods, leukapheresis and collection of peripheral blood in metastatic prostate cancer patients. The main questions it aims to answer are: 1. The advantages and disadvantages of two sampling methods for further diagnosis and treatment; 2. How to obtain further information on the tumour biology of CTC; 3. The mechanisms of prostate cancer invasion and metastasis Participants will have 7.5mL of peripheral blood taken as well as undergo leukapheresis.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 50 (estimated)
- First submitted
- 13 Jun 2024
- Start date
- Jun 2024
- Primary completion date
- Dec 2028
- Lead sponsor
- RenJi Hospital
- Diseases
- Prostate cancer
- NCT number
- NCT06469710
What you commit to
- Study type: Observational
- Planned participants: 50
- From Jun 2024 to the primary completion date, Dec 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- those who have received systemic combination therapy for tumours within 5 years;
- those receiving exogenous plasma at the time of the trial;
Other illness
- those with poor general condition, severe haemodynamic instability, malignant arrhythmias, cachexia and infections
Lab values
- those with coagulation disorders, DIC or reduced platelets;
Who the study is looking for
- male, aged 18-75 years; and
- Evidence of metastasis (positive finding of metastasis on one of the following tests: CT and MRI; whole-body nuclear bone imaging, fluoride PET and PET-CT, cholinergic PET-CT and MRI; prostate-specific membrane antigen-targeted PET-CT); or clinical diagnosis of metastatic prostate cancer (tumour stage of T3 and above) by pathology of aspiration/surgical biopsy;
- Good general condition, ECOG score 0-1, able to tolerate leukapheresis;
- Normal haematological analysis, liver and renal function tests at screening;
- Subjects (or their legal representatives) can understand the informed consent form.
Age in the registry: 18 years to 75 years · Sex: Male · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Renji Hospital, Shanghai Jiao Tong University Coordinator of this site? Confirm its status | Shanghai | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.